Other Balance Sheet Details (Tables)

12 Months Ended

Dec. 31, 2021

Balance Sheet Related Disclosures [Abstract]

Inventory

nventory consists of the following:

	December 31,
(In thousands)	2021		2020
Raw materials	$	1,301	$	391
Work in process	2,387		243
Finished goods	1,804		392
Total	$	5,492	$	1,026

Other Current Assets

Other current assets consist of the following:

	December 31,
(In thousands)	2021		2020
Receivable for U.K. R&D tax relief scheme	$	12,359	$	—
Note receivable from Tevard	5,000		—
Receivable under collaboration agreement	3,000		1,500
Other	4,376		3,436
Total	$	24,735	$	4,936

Property and Equipment, Net

Property and equipment, net consists of the following:

	December 31,
(In thousands)	2021		2020
Computer equipment and software	$	233	$	429
Leasehold improvements	9,998		9,835
Furniture and fixtures	1,134		1,266
Total	11,365		11,530
Less accumulated depreciation	(4,168)		(2,806)
Property and equipment, net	$	7,197	$	8,724

Other Long-Term Liabilities

Accrued and other current liabilities consist of the following:

	December 31,
(In thousands)	2021		2020
Accrued clinical trial costs	$	13,537	$	16,477
Accrued compensation	16,399		10,917
Accrued milestone payment	—		15,000
Accrued license amendment fee	7,000		—
Accrued royalties	4,250		479
Other accrued liabilities	14,227		12,091
Total	$	55,413	$	54,964